GlassScriptPhysician profile
Austin Brooks Smith
NPI 1619574639
$1,713.34
in general payments reported to CMS, 2019-2025
17 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.67 · 2023: $592 · 2024: $437 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.26 | 2023-2025 | |
| Lundbeck LLC | $247.31 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $180.40 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $157.19 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $134.15 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $117.09 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $112.84 | 2022-2025 | Trintellix, Vyvanse |
| Supernus Pharmaceuticals, INC. | $93.41 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $93.07 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $82.26 | 2023 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.75 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $49.86 | 2023-2024 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $32.15 | 2024-2025 | Hetlioz, Fanapt |
| Tris Pharma INC | $17.72 | 2023 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.83 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.90 | 2024 | Wellbutrin |
| Idorsia Pharmaceuticals US INC | $13.15 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.